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2634Objective: To describe the pharmacokinetics and tissue disposition of prophylactic cefazolin into skeletal
muscle in a pediatric population undergoing cardiac surgery.
Methods: The subjects included 12 children, with a median age of 146 days (interquartile range, 136-174) and
median weight of 5.5 kg (interquartile range, 5.2-7.3) undergoing cardiac surgery and requiring cardiopulmo-
nary bypass with or without deep hypothermic circulatory arrest. Institutional cefazolin at standard doses of
25 mg/kg before incision and 25 mg/kg in the bypass prime solution were administered. Serial plasma and
skeletal muscle microdialysis samples were obtained intraoperatively and the unbound cefazolin concentrations
measured. Noncompartmental pharmacokinetic analyses were performed and the tissue disposition evaluated.
Results: After the first dose of cefazolin, the skeletal muscle concentrations peaked at a median microdialysis
collection interval of 30 to 38.5 minutes. After the second dose, the peak concentrations were delayed a median
of 94 minutes in subjects undergoing deep hypothermic circulatory arrest. Skeletal muscle exposure to cefazolin
measured by the area under concentration time curve 0-last measurement was less in the subjects who underwent
deep hypothermic circulatory arrest than in those who received cardiopulmonary bypass alone (P ¼ .04). The
skeletal muscle concentrations of cefazolin exceeded the goal concentrations for methicillin-sensitive Staphy-
lococcus aureus prophylaxis; however, the goal concentrations for gram-negative pathogens associated with sur-
gical site infections were achieved only 42.1% to 84.2% and 0% to 11.2% of the intraoperative time in subjects
undergoing cardiopulmonary bypass alone or deep hypothermic circulatory arrest, respectively.
Conclusions: This cefazolin dosing strategy resulted in skeletal muscle concentrations that are likely not
effective for surgical prophylaxis against gram-negative pathogens but are effective against methicillin-
sensitive S aureus in infants undergoing cardiac surgery. (J Thorac Cardiovasc Surg 2014;148:2634-41)Cardiopulmonary bypass (CPB) with or without deep
hypothermic circulatory arrest (DHCA) can have
physiologic alterations that affect drug pharmacokinetics
(PK) and drug disposition.1,2 In neonatal and infant
populations, these PK changes are likely exacerbated,
given the larger ratio of CPB priming volume to
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The Journal of Thoracic and Cardiovascular Surmaturation.1 These factors can alter the blood and tissue
concentrations of medications, including the prophylacti-
cally administered antibiotics used to help prevent surgical
site infections (SSIs).
Pediatric cardiac surgical patients have estimated SSI
rates of 1.7 to 8.0 per 100 cases.3-9 Major postoperative
infections in these populations have been shown to
increase both the hospital length of stay and the mortality.8
Existing published data have identified procedure-related
factors, including intraoperative hypothermia, incorrect
timing of preoperative antibiotic administration, and surgery
duration, and patient-related factors that place some
children undergoing cardiac surgery at greater risk of
SSIs.3-13 Although most bacterial pathogens causing SSIs
in this population are gram-positive organisms, gram-
negative bacteria have been responsible for a significant
proportion of emerging infections.3-7,9-12,14
Critical for the prevention of SSIs is the use of a dosing
schedule of prophylactic antibiotics that achieves and main-
tains adequate tissue concentrations of antibiotics near the
surgical site.15-17 Microdialysis is a minimally invasive
method used in clinical pharmacology to directly and
continuously sample free, unbound analyte concentrationsgery c December 2014
Abbreviations and Acronyms
AUC ¼ area under the concentration time curve
CPB ¼ cardiopulmonary bypass
DHCA ¼ deep hypothermic circulatory arrest
MIC ¼ minimum inhibitory concentration
PD ¼ pharmacodynamics
PK ¼ pharmacokinetics
RR ¼ relative recovery
SSI ¼ surgical site infection
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Din the interstitial fluid of various tissues.18,19 PK studies of
prophylactic antibiotics during CPB in children have used
both total and unbound plasma concentrations as a
surrogate for the tissue drug concentrations.20-23 However,
the plasma concentrations might not accurately reflect the
antimicrobial exposures in the tissue where an infection
occurs. Tissue concentrations might represent the true
target for SSI prevention and could be important to
better determine the recommendations for prophylactic
antibiotic dosing.
The purpose of the present study was to determine the
PK and tissue disposition into the skeletal muscle of
prophylactic cefazolin, a commonly used first-generation
cephalosporin, using both plasma sampling and microdial-
ysis sampling in skeletal muscle in a homogeneous
population of infants with single ventricle physiology
undergoing CPB with and without DHCA.METHODS
Subjects and Surgical Procedure
The institutional review board at The Children’s Hospital of
Philadelphia approved the present PK study. The study protocol met all
applicable safety and reporting guidelines, with informed consent obtained
from the legal guardians of all subjects.
Children with single ventricle physiology who received cefazolin dur-
ing a procedure involving superior vena cava–pulmonary anastomosis
without pre-existing renal or hepatic dysfunction and no established allergy
to cefazolin were eligible. The anesthetic technique was at the discretion of
the attending cardiac anesthesiologist but generally included premedica-
tion with oral pentobarbital, induction of anesthesia with sevoflurane in
nitrous oxide/oxygen, and maintenance of anesthesia with isoflurane,
fentanyl, pancuronium or vecuronium, and dexmedetomidine. The
cefazolin dosing schedule used was institutional standard-of-care at the
study procedures and was as follows: 25 mg/kg given intravenously within
1 hour before incision and 25 mg/kg added to the CPB priming volume
(referred to henceforth as the ‘‘second dose’’ or ‘‘dose 2’’).
Description of CPB Procedures
All patients underwent CPB, with 7 patients also receiving DHCA.
The patients received heparin (200 U/kg) before initiation of CPB, with
an activating clotting time target of>480 seconds (Hemochron Response;
International Technidyne Corp, Edison, NJ). The CPB circuits were primed
with PLASMA-LYTE A (Baxter International, Deerfield, Ill), 25%
albumin, sodium bicarbonate, calcium gluconate, heparin sodium,
furosemide, pancuronium, or vecuronium, with or without aminocaproic
acid, whole blood, packed red blood cells, and cefazolin (25 mg/kg).The Journal of Thoracic and CarAll patients received methylprednisolone before CPB or in the CPB prime
and mannitol after crossclamp removal. The extracorporeal circuits
consisted of a membrane oxygenator (CAPIOX RX05 Baby RX or
CAPIOX RX15; Terumo, Tokyo, Japan), polyvinylchloride tubing
(Terumo), and roller pumps (Jostra HL 20; Maquet, Rastatt, Germany; or
St€ockert SIII; Sorin Group, Milan, Italy). For DHCA, hypothermia was
induced for 15 to 20 minutes to a target venous temperature of 18C
with rewarming for 22 to 25 minutes after reinitiation of CPB. Modified
ultrafiltration was performed after separation from CPB in all patients.PK Sampling
Blood samples (2 mL of blood collected in lithium heparin tubes)
were obtained from a site separate from that of cefazolin administration
by way of either an existent arterial catheter or from the CPB circuit.
Microdialysate samples were collected continuously throughout the
operative procedure. The blood and microdialysate samples were collected
simultaneously at times relative to each cefazolin dose (before the dose and
5, 15, 30, 60, 90, and 120 minutes after), immediately before and after
DHCA (if DHCAwas used), and at sternum and skin closure. The plasma
samples were separated into 2 aliquots: 1 to measure the total (protein
bound plus unbound) cefazolin concentration and 1 to measure the
unbound cefazolin concentration.Microdialysis Description
Microdialysis was performed using linear microdialysis catheters (66
Linear Catheter; M Dialysis AB, Solna, Sweden) inserted percutaneously
into the left deltoid muscle after the induction of anesthesia and was
removed after skin closure before the patient’s emergence from anesthesia.
The deltoid muscle was chosen for sample collection accessibility during
surgery and represents disposition of cefazolin into a skeletal muscle.
The catheters had polyarylethersulfone membranes with a molecular
weight cutoff of 20,000 Daltons and 10 mm length. The fluid used to
perfuse the microdialysis catheter was an isotonic solution designed for
use in peripheral tissue (Perfusion Fluid T1; M Dialysis AB). A 107
Microdialysis Pump (M Dialysis AB) with a flow rate of 1 mL/min was
used for microdialysate sample collection.
Relative Recovery and Interstitial Fluid
Concentration Calculations
The in vivo relative recovery (RR) of cefazolin in each microdialysis
catheter was calculated using retrodialysis. For retrodialysis, the
perfusion fluid was prepared by our Investigational Pharmacy and
contained 20 mg/mL of cefazolin and was run with a perfusion rate of
1 mL/min for 30 minutes before collection of the retrodialysis sample.
The in vivo RR was calculated for each subject using the following
equation19:
In vivo

RR
 
%
 ¼ 100 100 3 Cdialysate

Cperfusate

:
where Cdialysate is the cefazolin concentration in the retrodialysis sample
and Cperfusate is the concentration of cefazolin in the perfusion fluid that
was run during retrodialysis. After retrodialysis, the catheters were flushed
with the Perfusion Fluid T1 (not containing cefazolin) followed by a
median equilibration period of 21.5 minutes (interquartile range [IQR],
19.0-26.0 minutes) at a flow rate of 1 mL/min before the administration
of the first dose of cefazolin. The interstitial concentration of cefazolin
was then calculated using the following equation:
Interstitial Concentration ¼ 100
3 ðconcentration in microdialysate=in vivo RRÞ;
where the concentration in the microdialysate is the cefazolin concentra-
tion measured in the collected specimens.diovascular Surgery c Volume 148, Number 6 2635
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DSample Analysis
The blood samples were centrifuged at 2500 rpm for 10 minutes, sepa-
rated into 2 aliquots, stored at 20C at collection, and then stored at
80C. One aliquot was processed further by ultrafiltration of 400 mL of
plasma with a Spin-X ultrafiltrate membrane (10,000 molecular weight
cutoff; Corning Inc, Lowell, Mass) to measure unbound cefazolin.
Nonspecific binding of cefazolin to the ultrafiltration membrane was
12%, and this was corrected for in the final calculations. Two unbound
plasma concentrations (total of 120 measurement points) were
estimated according to the average protein binding for other similar
samples.
The cefazolin concentrations in the microdialysate (unbound only) and
plasma samples (total and unbound) were determined using validated
assays24 and high-performance liquid chromatography and tandem mass
spectrometry developed and performed at The Children’s Hospital of
Philadelphia. Total plasma samples (25 mL) were mixed with an internal
standard solution (5 mg/mL ampicillin in water) before protein precipita-
tion with 500 mL cold methanol and then diluted with 500 mL water before
centrifugation. Next, 100 mL of the supernatant was placed onto a 96-well
plate. Unbound plasma samples and microdialysate samples were assayed
for cefazolin by adding 10 mL of these samples directly to a 96-well plate
followed by 500 mL of the internal standard (40 ng/mL ampicillin in water).
For all samples, the high-performance liquid chromatography injection
volume was 5 mL, and chromatographic separation was achieved using a
HyPurity C18 Column (50 3 2.1 3 3 mm; Thermo Scientific, Waltham,
Mass), with mobile phase A consisting of 5 mM ammonium acetate in wa-
ter (pH 4.7) and mobile phase B consisting of 5 mM ammonium acetate in
90/10 acetonitrile/water. Cefazolin and ampicillin were detected using an
API4000 Qtrap mass spectrometer (AB Sciex, Redwood City, Calif).
The lower limit of quantification for the total plasma assay was 1 mg/mL
(linear range, 1-500), with inter- and intraday coefficients of variation of
<5%. For the unbound cefazolin, the lower limit of quantification was
0.1 mg/mL (linear range, 0.1-100), with inter- and intraday coefficients
of variation of<5%.
PK and Statistical Analysis
Noncompartmental methods were used for the PK analyses. The
maximum plasma and skeletal muscle concentration (Cmax) and the
time to the maximum concentration were determined after each cefazolin
dose. Owing to the nature of the microdialysis collection, the Cmax for the
microdialysis samples represented the average concentrations during the
collecting interval.
The area under the concentration time curve (AUC) for the plasma
samples was calculated using the log-linear trapezoid method. For the
microdialysis samples, the skeletal muscle AUC was calculated by
multiplying the measured unbound cefazolin concentration corrected for
RR by the interval of the microdialysis sample collection and then the
summation of the areas for each interval. Calculation of the AUC from
0 to the last measurement (AUC0-last) allows for a measure of cefazolin
exposure in both plasma and skeletal muscle for the duration of the
intraoperative sample collection period. Tissue penetration of cefazolin
was determined by calculating, and comparing, the ratios of AUC0-last
for the microdialysis samples to the AUC0-last for the unbound plasma
samples.
The PK-pharmacodynamic (PD) factor most closely associated with
the antibacterial effectiveness of cephalosporins is the amount of time
the concentration of the free drug exceeds the minimum inhibitory
concentration (MIC) for bacterial growth (fT>MIC).25 Therefore, this
value was calculated using the relevant MIC required to inhibit the growth
of 90% of organisms (MIC90) values.
26
The summary data are presented as the median and IQR. Nonparametric
tests, including the Wilcoxon signed rank test and the Wilcoxon rank sum
test, were used for comparison statistics. Statistical analyses and plots were
performed using R (R Project for Statistical Computing, Vienna, Austria),2636 The Journal of Thoracic and Cardiovascular SurMicrosoft Excel (Microsoft, Redmond, Wash), and S-PLUS (TIBCO
Software, Inc, Palo Alto, Calif).
Safety and Monitoring
Each subject had a microdialysis adverse event monitoring form
completed after catheter placement and daily until hospital discharge or
7 days postoperatively to assess for complications related to the
microdialysis catheters.RESULTS
Population Characteristics
A convenience sample of 14 subjects was enrolled in
the present study, with complete data obtained from 12
(Table 1). For 1 subject, the microdialysis catheter did not
function, and no microdialysate or blood samples were
collected, and 1 subject had not received the correct
cefazolin dose. No SSIs developed in the present cohort.PK Parameters
The timing and duration of CPB and DHCA varied for
every patient. After administration of the first cefazolin
dose, the unbound plasma cefazolin concentrations had
peaked at the first measured point (Cmax1 and time to
maximum concentration 1) and then had decreased
exponentially. The minimum concentration measured
before dose 2 was 13.5 mg/mL (IQR, 10.9-16.0). The second
dose was administered 37.5 minutes (IQR, 31.8-49.0) after
the initial dose and produced a second unbound plasma
peak of similar concentration (Cmax2) and time (time to
the maximum concentration 2) to the first dose (Table 2,
Figure 1).
After administration of the first cefazolin dose, the
muscle concentrations of cefazolin started to increase
within 5 to 15 minutes but had not peaked until 30 to 45
minutes for both groups (Table 2, Figure 2). However, after
the second cefazolin dose, peak muscle concentrations
were observed at a median of 31 to 52 minutes for the
CPB-only group and were delayed to a median of 94
minutes for the CPB plus DHCA group (Table 2). After
the first cefazolin dose, both groups had similar calculated
clearances (Table 2); however, the calculated clearance
(determined from the total dose received) during the study
period was decreased in the subjects who had undergone
CPB plus DHCA (Table 2, Figure 1).Tissue Penetration
The median in vivo RR was 28.6% (IQR, 21.5%-
30.8%). The skeletal muscle to unbound plasma AUC0-last
ratio was significantly less in the CPB plus DHCA group
than in the CPB-only group. This was driven by the
greater unbound plasma AUC0-last in the CPB plus
DHCA group (Table 2), indicating delayed plasma
clearance.gery c December 2014
TABLE 1. Subject characteristics (n ¼ 12)
Variable
CPB
(n ¼ 5)
CPB þ DHCA
(n ¼ 7)
P
value
Age (d) .53
Median 141 160
IQR 129-150 140-184
Sex .56
Male 2 5
Female 3 2
Weight (kg) 1
Median 5.5 5.8
IQR 4.9-7.2 5.4-7.3
Length (m) .87
Median 0.61 0.63
IQR 0.59-0.67 0.58-0.65
Interval from cefazolin dose
1 to incision (min)
.81
Median 5.5 5.5
IQR 4.5-9.0 3.3-7.8
Interval from cefazolin dose
1 to dose 2 (min)
.20
Median 35.0 40.0
IQR 30.0-39.0 34.0-59.0
Actual cefazolin dose 1 (mg/kg) .22
Median 25.3 25.0
IQR 25.0-25.5 25.0-25.1
Actual cefazolin dose 2 (mg/kg) .39
Median 25.0 25.0
IQR 25.0-25.1 25.0-25.0
CPB prime volume (mL) .37
Median 450 425
IQR 430-500 400-437
CPB or total support time (min) .03
Median 35.7 64.1
IQR 33.0-38.4 60.3-92.6
DHCA time (min) —
Median NA 24.8
IQR 22.0-44.4
Total surgical time (min) .09
Median 123.8 163.0
IQR 99.3-153.9 126.7-437.5
Procedure start temperature (C) .93
Median 36.4 36.4
IQR 35.9-36.6 35.8-36.7
Lowest core temperature (C) .003
Median 33.3 17.8
IQR 33.1-35.8 16.8-18.2
Procedure end temperature (C) .19
Median 37.2 35.9
IQR 36.3-37.2 35.6-36.6
Surgical procedures (n) —
Bidirectional Glenn 5 1
Bilateral bidirectional Glenn 0 3
Kawashima 0 2
Hemi-Fontan 0 1
Categorical data were compared using Fisher’s exact test and continuous data
using the Wilcoxon rank sum test. CPB, Cardiopulmonary bypass; DHCA, deep
hypothermic cardiac arrest; IQR, interquartile range; NA, not applicable.
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DfT>MIC Value
For all subjects, approximately 100% of the sampling
period showed unbound cefazolin concentrations in both
plasma and skeletal muscle of>2 mg/mL (Table 3). This
percentage decreased for both groups for concentrations
>16 mg/mL and >32 mg/mL in the plasma or skeletal
muscle, respectively. The most pronounced decrease was
noted in the skeletal muscle of the subjects who underwent
DHCA (Table 3).
Protein Binding
Cefazolin is known to demonstrate concentration-
dependent protein binding.27 In the present study,
the median percentage of protein binding of cefazolin
for all collected plasma samples was 84.8% (IQR,
79.8%-88.0%). However, the percentage of protein binding
of cefazolin in plasma samples collected during DHCAwas
78.9% (IQR, 77.3%-81.9%), significantly less than that in
those samples collected at other times that showed a median
of 85.5% (IQR, 81.3%-88.7%; P ¼ .002).
Microdialysis Catheter Safety
Of the 12 subjects, 6 experienced minor bleeding
(defined as 1-3 drops of blood) on placement of the
catheters and 3 experienced minor bleeding on removal.
No subjects experienced subcutaneous bleeding during
anticoagulation. No complications attributable to the
microdialysis catheters occurred for7 days after removal.
DISCUSSION
The purpose of the present study was to describe the
plasma and skeletal muscle PK and tissue disposition of
cefazolin in a homogeneous group of young children
undergoing open heart surgery with and without DHCA.
This is the first published study to use microdialysis in a
pediatric surgical population for application in clinical
pharmacology.
The cefazolin dosing strategy used during the present
study resulted in skeletal muscle concentrations that were
likely effective for prophylaxis against methicillin-
sensitive Staphylococcus aureus (MIC90  2 mg/mL)
throughout procedures that require CPB with or
without DHCA. However, gram-negative organisms and
Staphylococcus epidermidis, some of which might be sus-
ceptible to cefazolin, comprise a significant proportion of
the reported epidemiology of SSIs in pediatric cardiac sur-
gical patients.3-7,9-12,14 The dosing regimen used in the
present study might be inadequate to prevent infections
by those pathogens with an MIC90 of 32 mg/mL in
patients undergoing CPB or by those pathogens with an
MIC90 of 16 mg/mL in patients undergoing CPB with
DHCA. Unlike PD measures of cephalosporin efficacy for
treatment of active infections (goal, 4-5 3 MIC90 valuediovascular Surgery c Volume 148, Number 6 2637
TABLE 2. Pharmacokinetic parameters for cefazolin for all subjects
Parameter All subjects (n ¼ 12) CPB only (n ¼ 5) CPB þ DHCA (n ¼ 7)
Tmax1 unbound plasma (min) 5.0 (5.0-6.0) 5.0 (5.0-5.0) 6.0 (5.5-6.0)
Cmax1 unbound plasma (mg/mL) 45.7 (35.0-56.4) 40.6 (35.3-54.1) 50.7 (35.8-58.4)
Tmax1 MD (min) 30.5-38.5 30-35 31-45
Cmax1 MD (mg/mL) 17.9 (8.7-34.1) 31.6 (18.9-58.1) 15 (8.7-25.5)
Tmax2 unbound plasma (min) 5.0 (5.0-7.5) 5.0 (5.0-5.0) 5.0 (5.0-10.0)
Cmax2 unbound plasma (mg/mL) 50.9 (42.8-60.6) 41.6 (36.7-61.3) 52.3 (48.8-58.5)
Tmax2 MD (min) 64.5-82.5 31-52 94
Cmax2 MD (mg/mL) 29.6 (15.9-60.7) 60 (30.0-62.7) 16.5 (13.9-42.9)
MD/unbound plasma AUC ratio 0.7 (0.4-1.2) 1.2* (0.8-1.3) 0.4* (0.3-0.7)
MD AUC0-last (mg 3 min/mL) 2432.2 (1823.1-5794.8) 3271.1 (2512.2-5802.0) 2230.3 (1613.18-4072.22)
Unbound plasma AUC0-last (mg 3 min/mL) 4881.0 (3068.2-5480.5) 2883.0y (2613.6-3129.9) 5063.3y (4892.4-6830.3)
Calculated dose 1 clearance (L/h/kg) 1.6 (1.4-1.9) 1.7 (1.5-2.5) 1.5 (1.4-1.7)
Calculated intraoperative clearance (L/h/kg) 0.6 (0.6-1.0) 1.4z (1.0-1.2) 0.6z (0.4-0.6)
Data presented as median (IQR), except for the Tmax values for theMD samples. Tmax data for MD samples presented as median values of the time collection interval over which
the likely peak was collected, because the measured microdialysate concentrations represent average concentrations over the collected period and not precise point estimates.
CPB, Cardiopulmonary bypass;DHCA, deep hypothermic circulatory arrest; Tmax1 and Tmax2, time to maximum concentration at first and second measured point, respectively;
Cmax1 and Cmax2, maximum concentration at first and second measured point, respectively; MD, microdialysis; AUC, area under the concentration time curve; AUC0-last,
calculation of the AUC from 0 to the last measurement. *P ¼ .04. yP ¼ .01. zP ¼ .01.
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Dfor 60%-70% of the dosing interval25), no clear guidelines
are available for the antibiotic concentrations necessary for
prophylactic dosing. Devoid of accepted definitions, our
assessment of SSI efficacy was very conservative and
based only on the requirement that the skeletal muscle
concentrations surpass the MIC90 for>60% of the dosing
interval. Because the postantibiotic effect of cefazolin isFIGURE 1. Semilogarithmic concentration time profile for unbound cefazolin
bypass (CPB). The horizontal lines indicate the various concentration targets a
the initiation of CPB. DHCA, Deep hypothermic circulatory arrest; E coli,
Staphylococcus epidermidis; MSSA, methicillin-sensitive Staphylococcus aureu
2638 The Journal of Thoracic and Cardiovascular Surless for gram-negative organisms,25 our assessment might
be even more of an underestimate for these organisms
compared with methicillin-sensitive S aureus.
Because fT>MIC is the most important PD parameter
when assessing cefazolin dosing and bacteria that reside
on the skin are the main pathogens causing SSIs, it seems
prudent to attempt to achieve adequate tissue concentrationsin plasma of all subjects referenced from the initiation of cardiopulmonary
nd associated surgical site infection pathogens. The vertical line indicates
Escherichia coli; K pneumonia, Klebsiella pneumonia; S epidermidis,
s.
gery c December 2014
FIGURE 2. Semilogarithmic concentration time profile for unbound cefazolin in skeletal muscle of all subjects referenced from the initiation of
cardiopulmonary bypass (CPB). The horizontal lines indicate the various concentration targets and associated surgical site infection pathogens. The
vertical line indicates the initiation of CPB. DHCA, Deep hypothermic circulatory arrest; E coli, Escherichia coli; K pneumonia, Klebsiella pneumonia;
S epidermidis, Staphylococcus epidermidis; MSSA, methicillin-sensitive Staphylococcus aureus.
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Dof antibiotics before the surgical incision. Our results
support the course of increasing tissue concentrations
that has been demonstrated in several adult surgical
populations.28-30 This could partially have resulted from a
limitation of microdialysis as a sampling method, because
it relies on equilibration across a semimembrane and we
were measuring average concentrations for the collection
interval. However, we attempted to mitigate this effect
during the present study by timing the microdialysis
sampling with each plasma sample.
CPB can change the PK owing to many factors, including
hemodilution, differing compositions of prime fluid
affecting protein binding, the pH management strategy
used, altered renal and hepatic blood flow resulting in
changes in clearance, the effects of hypothermia andTABLE 3. Percentage of time cefazolin concentrations were greater than
Concentration
target (mg/mL) SSI pathogen
All subjects (n ¼ 12)
Unbound plasma Skeletal muscle U
2 MSSA 100 (100-100) 100 (99.2-100)
16 E coli, K
pneumoniae
93.6 (68.9-94.6) 55.5 (1.7-86.1) 6
32 S epidermidis
Enterobacter sp
43.7 (32.7-51.0) 0.0 (0.0-66.7) 1
Data presented as median percentage (IQR). Each concentration target represents an estim
in pediatric cardiac surgical patients. SSI, Surgical site infection; CPB, cardiopulmonar
Staphylococcus aureus; E coli, Escherichia coli; K pneumonia, Klebsiella pneumonia; S e
The Journal of Thoracic and Carcirculatory arrest, and the systemic inflammatory reaction
induced by CPB.1 In addition, sequestration of cefazolin
by the CPB circuit might have a significant effect on the
available drug for disposition into tissue.31 In the present
study, the skeletal muscle concentrations were starting to
decrease just before or immediately after the initiation of
CPB for all patients. After the second dose of cefazolin,
the skeletal muscle concentrations again started to increase
and was maintained at a value similar to that of the pre-CPB
maximum concentration until the end of the procedure in
both groups, although the unbound plasma cefazolin
exposure was less in the CPB-only group. Although we
did not have a comparison group that did not undergo
CPB, in a piglet model of pediatric CPB subjects that
underwent median sternotomy without CPB showed peakdifferent concentration targets
CPB only (n ¼ 5) CPB þ DHCA (n ¼ 7)
nbound plasma Skeletal muscle Unbound plasma Skeletal muscle
100 (100-100) 100 (100-100) 100 (100-100) 100 (99.2-100)
9.8 (65.1-93.1) 84.2 (74.6-91.9) 94.4 (89.8-97.9) 11.2 (0.5-55.5)
6.3 (12.0-47.4) 42.1 (0-72.6) 45.6 (40.5-57.4) 0 (0-0)
ated MIC90 of bacteria potentially susceptible to cefazolin and known to cause SSIs
y bypass; DHCA, deep hypothermic circulatory arrest; MSSA, methicillin-sensitive
pidermidis, Staphylococcus epidermidis.
diovascular Surgery c Volume 148, Number 6 2639
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Dtissue concentrations of 15 to 30 minutes after administra-
tion, followed by a steady decrease in the concentration
(T. Kilbaugh, unpublished data). Therefore, a second dose
of cefazolin or, potentially, a continuous infusion of
cefazolin might be important for maintenance of goal tissue
concentrations of cefazolin, especially given the increased
volume of distribution during CPB.
We demonstrated decreased tissue disposition of cefazo-
lin into the skeletal muscle during DHCA despite the
decreased plasma clearance and resultant greater overall
plasma exposure (AUC) to the drug. We postulated that
the decrease in diffusion of the unbound cefazolin into the
muscle interstitium results from a combination of alter-
ations in drug delivery and microcirculation secondary to
induced circulatory arrest and deep hypothermia. Protein
binding of cefazolin was less during the periods of DHCA
and, if anything, would bias the findings more toward
unbound cefazolin being more available for distribution
into the surrounding tissue. Hypothermia, circulatory arrest,
and operative time have all been described as risk factors for
SSIs after pediatric cardiac surgery, with variable strengths
of association.3-5,10,13,14 Although these factors all likely
influence the tissue disposition of cefazolin, we are not
able to comment on the relative importance of each factor.
In the present study, the subjects with the greatest plasma
concentrations of total or unbound cefazolin did not neces-
sarily have the greatest skeletal muscle concentrations of
unbound cefazolin throughout the course of the surgical
procedure (eg, subjects 1, 6, and 9). These differences
were most profound during DHCA, suggesting that plasma
levels might not be predictive of the skeletal muscle concen-
trations in all patients, highlighting one of the limitations of
previous studies of prophylactic antibiotics in children
undergoing CPB using the plasma level as a surrogate for
the tissue concentration.20-23 Furthermore, despite the
routine use of cefazolin for SSI prophylaxis in congenital
cardiac surgery, only 1 published study has measured
cefazolin in plasma, and that study was limited because it
did not report the unbound cefazolin levels or tissue
concentrations.21
The most common side effect related to the microdialysis
catheters was minor bleeding (defined as 1-3 drops of
blood) at the insertion sites. No cases of significant bleeding
(defined as >1 mL of blood) nor of local or systemic
infection related to the microdialysis catheter occurred.
These results are congruent with the only dedicated micro-
dialysis safety report in the pediatric data32 and demonstrate
the feasibility and safety of using microdialysis during
pediatric cardiac surgical procedures.
The study limitations included that we studied an infant
population requiring cardiac surgery with CPB with or
without DHCA. Thus, our results might not be applicable
to all neonates, older children and adolescents, or
patients with 2-ventricle physiology. In addition, the goal2640 The Journal of Thoracic and Cardiovascular Surof our study was to measure the unbound cefazolin
concentrations in the skeletal muscle during the surgical
procedure; therefore, we restricted the sampling period to
the intraoperative time. We did not fully characterize
cefazolin clearance using modified ultrafiltration. No sub-
ject from our cohort developed an SSI; thus, we could not
correlate any PK variability with the development of a post-
operative infection.
The microdialysis catheters were placed in the deltoid
muscle to avoid complications arising from interference
in the operative field. Therefore, we cannot comment on
local tissue concentrations closer to the surgical wound.
However, 1 adult study showed that the tissue concentra-
tions of cefazolin were lower when measured close to the
surgical wound than at sites separate from the surgical
site,30 again suggesting that our PD assessments were likely
overestimates. The importance of achieving adequate tissue
concentrations of prophylactic antibiotics for effectiveness
against SSIs has been recognized.16 Studies in adult
populations have linked tissue concentrations to wound
infections33,34; however, no such data have been reported
in published pediatric studies.
One recent large retrospective analysis suggested that a
significant modifiable risk factor for the prevention of
SSIs in pediatric patients is the appropriate administration
of prophylactic antibiotics.35 Our results suggest that the
current cefazolin dosing strategies could be flawed. The
timing of prophylactic cefazolin administration and a
second dose of cefazolin given on initiation of CPB are
important considerations for infants undergoing cardiac
procedures with CPB, with and without DHCA. Depending
on the local SSI epidemiology, in addition to optimization
of SSI prevention bundles, the dosing of cefazolin with
patients undergoing DHCA might need to be altered or
another agent considered if gram-negative organisms
constitute a high proportion of postoperative infections.
The present study has provided a model for future investiga-
tions of different prophylactic antibiotic dosing regimens
in pediatric surgical populations that should be
designed to better understand patient variability and to
develop evidence-based dosing recommendations that
achieve defined PD targets.References
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